We are live on !
Find out more
BVF Inc Portfolio holdings
AUM
$3.91B
Turnover
15.22%
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter Est. Return
-0.94%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.93%
10 Year Est. Return
+28,184.7%
AUM
$498M
AUM Growth
-$33M
(-6.2%)
Cap. Flow
+$1.65M
Cap. Flow % of AUM
Cap. Flow %
0.33%
Top 10 Holdings %
Top 10 Hldgs %
75.53%
Holding
33
New
4
Increased
9
Reduced
10
Closed
4
Avg Time Held
1.4
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Blueprint Medicines
BPMC
|
+$14.8M |
| 2 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$12.9M |
| 3 |
Fate Therapeutics
FATE
|
+$10.1M |
| 4 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
+$3.54M |
| 5 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$2.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
|
+$15.9M |
| 2 |
Array Biopharma Inc
ARRY
|
+$10.9M |
| 3 |
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
|
+$9.9M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$7.92M |
| 5 |
ChemoCentryx, Inc.
CCXI
|
+$1.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.4% |
| 2 | Miscellaneous | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Blueprint Medicines
BPMC
| $91.3M | 18.35% |
3,255,280
+490,200
| +18% | +$14.8M |
2015 Q2
6 quarters
|
|
2
Cytokinetics
CYTK
$7.68B
| $58.9M | 11.84% |
4,851,691
-145,380
| -3% | -$1.54M |
2013 Q2
14 quarters
|
|
|
3
DELISTED
ChemoCentryx, Inc.
CCXI
| $57.7M | 11.59% |
7,798,572
-265,447
| -3% | -$1.91M |
2013 Q2
14 quarters
|
|
|
4
DELISTED
Array Biopharma Inc
ARRY
| $43.8M | 8.81% |
4,986,186
-1,475,000
| -23% | -$10.9M |
2013 Q2
14 quarters
|
|
|
CNCE
5
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $26.9M | 5.41% |
2,616,249
-106,961
| -4% | -$978K |
2014 Q3
9 quarters
|
|
6
Xenon Pharmaceuticals
XENE
$3.92B
| $23.4M | 4.71% |
3,043,805
-65,100
| -2% | -$523K |
2014 Q4
8 quarters
|
|
|
FWP
7
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $20.8M | 4.19% |
198,265
| – | – |
2014 Q4
8 quarters
|
|
|
CTIC
8
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $18.1M | 3.63% |
4,479,694
| – | – |
2015 Q3
5 quarters
|
|
|
CLCD
9
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
| $17.6M | 3.54% |
484,335
-278,965
| -37% | -$9.9M |
2016 Q3
1 quarter
|
|
10
Crescent Biopharma
CBIO
$507M
| $17.2M | 3.46% |
28,263
+4,000
| +16% | +$2.5M |
2016 Q2
2 quarters
|
|
|
OMED
11
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $13.6M | 2.73% |
1,760,489
-51,516
| -3% | -$473K |
2013 Q3
13 quarters
|
|
|
CASC
12
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $13.5M | 2.71% |
3,133,224
-4
| -0% | -$26 |
2013 Q2
14 quarters
|
|
|
INFI
13
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $10.6M | 2.13% |
7,860,808
+2,711,164
| +53% | +$3.54M |
2016 Q2
2 quarters
|
|
|
ACHN
14
DELISTED
Achillion Pharmaceuticals
ACHN
| $10M | 2.01% |
+2,423,300
| New | +$12.9M |
2016 Q4
0 quarters
|
|
|
15
Fate Therapeutics
FATE
$236M
| $9.44M | 1.9% |
+3,759,398
| New | +$10.1M |
2016 Q4
0 quarters
|
|
|
ARQL
16
DELISTED
Arqule Inc
ARQL
| $9.32M | 1.87% |
7,400,128
| – | – |
2013 Q2
14 quarters
|
|
17
DELISTED
Esperion Therapeutics
ESPR
| $8.92M | 1.79% |
712,770
+218,898
| +44% | +$2.61M |
2016 Q1
3 quarters
|
|
|
KDNY
18
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $8.5M | 1.71% |
149,177
+48,946
| +49% | +$2.96M |
2016 Q2
2 quarters
|
|
|
IMDZ
19
DELISTED
Immune Design Corp.
IMDZ
| $7.26M | 1.46% |
1,320,164
+120,164
| +10% | +$849K |
2016 Q3
1 quarter
|
|
20
CytomX Therapeutics
CTMX
$432M
| $6.1M | 1.23% |
554,806
-37,007
| -6% | -$448K |
2015 Q4
4 quarters
|
|
21
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $5.85M | 1.18% |
7,917
-306
| -4% | -$327K |
2014 Q4
8 quarters
|
|
22
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $5.04M | 1.01% |
39,792
+18,925
| +91% | +$2.63M |
2015 Q3
5 quarters
|
|
23
DELISTED
Alpine Immune Sciences Inc
ALPN
| $4.18M | 0.84% |
466,119
+38,701
| +9% | +$771K |
2015 Q4
4 quarters
|
|
24
Palvella Therapeutics
PVLA
$2.54B
| $2.61M | 0.52% |
23,185
+10,478
| +82% | +$1.3M |
2016 Q2
2 quarters
|
|
25
Filana Therapeutics
FLNA
$24.8M
| $1.3M | 0.26% |
325,507
| – | – |
2015 Q3
5 quarters
|
|
Similar funds
LFCM
AC
BVF Inc's Q4 2016 Portfolio in Review
As of Q4 2016, BVF Inc held 33 positions worth $498M, down 6.2% from $531M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
BVF Inc's Q4 2016 filing shows 4 new, 9 increased, 10 reduced and 4 closed positions. Its largest new stake was Achillion Pharmaceuticals: 2,423,300 shares worth $10M. The largest sale was Tobira Therapeutics, Inc. Common Stock, an estimated $15.9M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
- BVF Inc's largest Q4 2016 buy was Achillion Pharmaceuticals: 2,423,300 shares worth $10M.
- BVF Inc added most to Blueprint Medicines in Q4 2016, an estimated $14.8M increase.
- BVF Inc's biggest Q4 2016 reduction was Array Biopharma Inc, cutting an estimated $10.9M.
- BVF Inc fully exited Tobira Therapeutics, Inc. Common Stock in Q4 2016, selling an estimated $15.9M.
- BVF Inc's ten largest holdings make up 76% of its $498M portfolio in Q4 2016.
- BVF Inc opened 4 new positions and closed 4 in Q4 2016.
- BVF Inc's portfolio value fell 6.2% quarter-over-quarter to $498M.
Based on BVF Inc's 13F filing for Q4 2016, filed 14 Feb 2017.